Sanofi's third-quarter earnings surged 25% in its vaccines division, driven by strong sales of Beyfortus, its RSV antibody for infants, which generated 645 million euros. Overall, the company reported total sales of $13.4 billion, exceeding Wall Street expectations and reflecting nearly 16% growth. The recent approval of a new manufacturing line aims to enhance Beyfortus supply amid high demand, ensuring access for all eligible infants in the U.S.
Sanofi's CEO, Paul Hudson, acknowledged "difficult discussions" with the French government regarding the sale of its OTC subsidiary, Opella, which markets Doliprane. The negotiations, under significant political pressure, resulted in commitments to maintain production in France and preserve jobs at local sites for at least five years. The French government will have a minor stake in Opella, ensuring governance without deterring foreign investment.
Sanofi is moving forward with a deal to sell a controlling 50% stake in its consumer health business, Opella, to Clayton Dubilier & Rice for approximately €16 billion ($17.3 billion). Bpifrance will hold a 2% minority stake, ensuring job security in France amid concerns over potential job losses. The transaction is expected to close by Q2 2025, allowing Sanofi to focus on its biopharmaceuticals.
The French government has secured strong guarantees in the sale of a 50% stake in Opella, producer of Doliprane, to American investment fund CD & R, which aims to enhance growth. The agreement includes a €70 million investment in France, job protection, and penalties for production stoppages. Sanofi retains a 48% stake, ensuring continued involvement in Opella's operations.
Sanofi is investing 300 million euros for a 16% stake in a new joint venture with Orano Med to develop radiopharmaceuticals targeting rare cancers, particularly using the radioisotope lead-212. This partnership aims to leverage expertise in biopharma and nuclear technology to advance cancer treatment. The joint venture is valued at 1.9 billion euros, following Sanofi's recent licensing of an experimental drug for neuroendocrine tumors.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
